ChromaDex Rides Nestle Deal To 14% Q4 Growth; Mannatech, USANA End Year In Slumps
ChromaDex reports Niagen ingredient sales growth propelled by upfront minimum purchase from Nestlé Health Science; and Mannatech and USANA both reported larger full-year sales dips after ending 2022 in slumps.
You may also be interested in...
US Q3 Health And Wellness Results: Chromadex, Lannett, Mannatech And USANA
ChromaDex trims loss, adds Nestle as Niagen customer; currency exchange slams Mannatech; Asia-Pacific sales, currency exchange Rock USANA results; and Lannett sees upsides after 25% sales slide.
Is It Time To Promote US FDA’s Biosimilars Office Out Of OND?
Making the Office of Therapeutic Biologics and Biosimilars a stand-alone office in CDER may allow it to add more expertise, but is there an appetite for another reorganization?
UK LifeSci Funding Boost – Medtech Research And Regulation To Benefit
Rebranded Health Innovation Networks, Biobanks and clinical trials get share of £650m UK funding earmarked to support research, manufacturing, skills development and access to diagnosis and treatment.